Table 4

Subgroup analysis results

Base case (all patients)BMI≥30 kg/m2 BMI≥35 kg/m2
SUSTAIN 4: Semaglutide 0.5 mg versus insulin glargine U100
ICER based on direct costs€11 310 per QALY gained€11 184 per QALY gained€13 205 per QALY gained
ICER based on combined costs€4988 per QALY gained€4541 per QALY gained€7463 per QALY gained
SUSTAIN 4: Semaglutide 1 mg versus insulin glargine U100
ICER based on direct costs€7515 per QALY gained€6384 per QALY gained€5564 per QALY gained
ICER based on combined costs€495 per QALY gainedSemaglutide dominantSemaglutide dominant
SUSTAIN 7: Semaglutide 0.5 mg versus dulaglutide 0.75 mg
ICER based on direct costs€4671 per QALY gained€3917 per QALY gained€2149 per QALY gained
ICER based on combined costsSemaglutide dominantSemaglutide dominantSemaglutide dominant
SUSTAIN 7: Semaglutide 1 mg versus dulaglutide 1.5 mg
ICER based on direct costs€2861 per QALY gained€2855 per QALY gained€3392 per QALY gained
ICER based on combined costsSemaglutide dominantSemaglutide dominantSemaglutide dominant

  • €, 2017 euros (EUR); BMI, body mass index; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.